Information on Non-Hodgkin Lymphoma from the National Library of Medicine (NIH)
Lymphoma is a cancer of a part of the immune system called the lymphatic system. There are many types of lymphoma. One type is called Hodgkin disease. The rest are called non-Hodgkin lymphoma. Read more at the National Library of Medicine, National Institutes of Health.
Information on Non-Hodgkin's Lymphoma from the MD Anderson Cancer Center
Lymphoma is a general term for cancers that develop in the lymphatic system (the tissues and organs that produce, store and carry white blood cells). Hodgkin's disease is one type of lymphoma. It develops in white blood cells, which help the body fight disease. All other lymphomas are grouped together and are called non-Hodgkin's lymphoma (NHL). They develop in other parts of the lymphatic system, including the bone marrow, spleen, thymus and lymph nodes and can then spread to other organs. Non-Hodgkin's lymphoma is the fifth most common type of cancer (not including skin cancer) in the United States today. Over 66,000 adults and children will be diagnosed with non-Hodgkin's lymphoma this year. Read more from the MD Anderson Cancer Center.
Information on Non-Hodgkin's Lymphoma from the Dana-Farber Cancer Institute
Adult Non-Hodgkin lymphoma is a disease in which malignant (cancer) cells form in the lymph system. The lymph system is part of the immune system. Read more from the Dana-Farber Cancer Institute.
Interactive Quiz: How Much Do You Know About Non-Hodgkin's Lymphoma?
Lymphomas are a type of cancer that affects the lymphatic system. Learn more about non-Hodgkin's lymphoma (NHL) by taking this true-false quiz from Meriter Health Services, based on information from the American Cancer Society (ACS) and the Lymphoma Research Foundation (LRF).
Interactive Quiz: Know Your Nodes
Many have heard of lymph nodes and know they are somewhere in the body, but beyond that, details about the lymphatic system and lymphoma often remain a mystery. Take some time to take the quiz, provided by Lymphoma Foundation Canada.
This is a tutorial about lymphomas: Non-Hodgkin lymphomas, Hodgkin lymphomas, and plasma cell dyscrasias. The emphasis is on how these lymphomas are diagnosed and what the important morphological and biological distinctions are among them. Review the tutorial, provided by the University of Medicine and Dentistry of New Jersey.
Podcast: Innovative therapies in Non-Hodgkin’s lymphoma
Each year, UNMC offers a mini-medical school, a medical school anyone can attend. This year's topic was Women and Cancer. This podcast series explores breakthroughs in research and therapies that are offering unprecedented hope for women with cancer. Listen to this podcast, presented by the University of Nebraska Medical Center.
Podcast: Living with cancer, Non Hodgkin’s Lymphoma
By Jayden, 17. Listen to this podcast, provided by the National Health Service, England.
Podcast: Non Hodgkin’s Lymphoma
In 2002, Dick Birnie was diagnosed with metastatic prostate cancer. Soon after, it was discovered that he also had indolent, or slow-growing, non-Hodgkin's lymphoma. His doctors began monitoring his non-Hodgkin's lymphoma, and over the next two years successfully treated him for prostate cancer. Six years later, Dick's non-Hodgkin's lymphoma became aggressive, requiring active treatment. In this episode, Dick reflects on his eight years of cancer treatment, and notes that Norris Cotton Cancer Center's support services played an important role in his care. Listen to this podcast, provided by the Dartmouth University Norris Cotton Cancer Center.
Lymphoma with Dr. Rick Hagemeister, a video presented by the MD Anderson Cancer Center.
Podcast: Advances in the Treatment of Lymphoma
There are 71,000 new cases of lymphoma diagnosed annually in the United States. Learn about new drug developments and innovative treatments such as vaccine therapy and bone marrow transplants in this podcast, presented by the MD Anderson Cancer Center.
Dr. Rick Hagemeister and his patient, Bill, in a video presented by the MD Anderson Cancer Center.
Video: Bone Marrow Donation
Stem cells or bone marrow could save someone's life. Elisè Collins, Dana-Farber's Donor Center manager, and Joseph Antin, MD, Chief of the Stem Cell Transplant Program at Dana-Farber/Brigham and Women's Cancer Center, explain how you can help. A video presented by the Dana-Farber Cancer Institute.
Video: Leukemia and Lymphoma Society: Team In Training
Every five minutes, someone in the United States learns that he or she has leukemia, Hodgkin or non-Hodgkin lymphoma or myeloma. Every ten minutes, someone dies of a blood cancer. In exchange for training and support, you help raise money towards cures for blood cancers like leukemia -- the No. 1 disease killer of children -- lymphoma and myeloma. Watch the video from the Leukemia and Lymphoma Society.
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
In people with relapsed stage III or IV follicular Non-Hodgkin's lymphoma, rituximab is now an option in combination with chemotherapy to induce remission or alone as maintenance therapy during remission. Rituximab monotherapy is also an option for people with relapsed or refractory disease when all alternative treatment options have been exhausted. See National Guideline Clearinghouse major recommendations.
Stem cell transplantation in adults: recommendations
The Non-Hodgkin's Lymphomas (NHLs) - Autologous stem cell transplantation is the recommended option for eligible chemosensitive patients with AH-NHL refractory to or relapsed after primary therapy. Allogeneic stem cell transplantation is an option for eligible chemosensitive patients with refractory or relapsed AH-NHL who are not candidates for autologous stem cell transplantation or who have a syngeneic (identical twin) donor. Stem cell transplantation is not recommended for patients with AH-NHL as part of primary therapy. See National Guideline Clearinghouse major recommendations.
Diagnostic imaging in lymphoma
These recommendations were developed by radiology and oncology experts in Ontario and are informed by research evidence and clinical expertise. See National Guideline Clearinghouse major recommendations.
Non-Hodgkin lymphoma: diagnosis and treatment
Non-Hodgkin lymphomas are a heterogeneous group of malignancies of the lymphoid system. Treatment of these diseases is based on the histology and extent of disease. Patients with follicular lymphomas with early-stage disease generally are treated with radiation therapy, whereas those with stage III and IV disease requiring treatment usually are treated with chemotherapy, Immunotherapy, or radioimmunotherapy. Full text available free through Pubmed.
Radiotherapy in Non-Hodgkin lymphomas
Most patients with localized Non-Hodgkin lymphoma (NHL) who receive radiotherapy (RT) are treated with the intent of achieving local control of disease. A palliative approach is used only when, due to the condition of the patient and/or the extent or location of the disease, a radical course of treatment carries no chance of local control. Full text available free through the Annals of Oncology.
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen, has therapeutic activity in diffuse large-B-cell lymphoma. We conducted a randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The addition of rituximab to the CHOP regimen increases the complete-response rate and prolongs event-free and overall survival in elderly patients with diffuse large-B-cell lymphoma, without a clinically significant increase in toxicity. Full text available free through the New England Journal of Medicine.
High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults
High-dose chemotherapy with autologous stem cell support (HDT) has been proven effective in relapsed aggressive non-Hodgkin lymphoma (NHL). However, conflicting results of HDT as part of first-line treatment have been reported in randomised controlled trials (RCTs). We undertook a systematic review and meta-analysis to assess the effects of such treatment. Conclusions - Despite higher CR rates, there is no benefit for high-dose chemotherapy with stem cell transplantation as a first line treatment in patients with aggressive NHL. Full text available free through Cochrane Reviews.
Sun exposure and Non-Hodgkin lymphoma
It was initially hypothesized that sun exposure might cause Non-Hodgkin lymphoma (NHL) on the following grounds: its incidence was increasing in parallel with that of cutaneous melanoma; its risk was increased in those with a history of melanoma or other skin cancer; sun exposure causes immune suppression; and immunosuppression for other reasons is associated with an increased risk of NHL. Three recent studies of NHL in individuals found that risk decreased, generally by 25% to 40%, across categories of increasing total or recreational, but not occupational, sun exposure. Full text available free through Pubmed.
Diffuse large B-cell lymphoma
Non-Hodgkin’s lymphoma rates, including DLBCL, have steadily increased 3 to 4% each year in the U.S. from 1973 to the mid 1990’s. Recent insights into the molecular heterogeneity of DLBCL are beginning to yield novel therapeutics with significant promise for key subsets of patients. Although CHOP chemotherapy with rituximab remains a standard therapeutic approach for most patients with DLBCL, we anticipate that novel agents will be included in treatment regimens for many patients in the near future. Full text available free through Pubmed.
Abstract: Treatment of aggressive Non-Hodgkin's lymphoma: a north American perspective
The most common subtype of aggressive Non-Hodgkin's lymphoma is diffuse large B-cell lymphoma (DLBCL). The era of monoclonal antibodies has transformed treatment practices for aggressive lymphoma and has led to a significant improvement in outcome. Read the abstract at Pubmed.
Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is a biologically heterogeneous disease for which the current approach to treatment is only successful for 50% of patients. The goal is to be able to identify subgroups of patients at high risk of treatment failure and develop more effective treatment based on specific biological defects that may represent new rational therapeutic targets. Full text available free through Pubmed.
Looking for a Top-Rated
Oncologist, Hematologist, or Primary Care Physician?
Consumers' Guide to Top Doctors finds the Doctors Rated Best by other Doctors
To find out who the top doctors are around the country, nonprofit Consumers' CHECKBOOK surveyed roughly 340,000 physicians to tell us which specialists they would want to care for a loved one. The Top Doctors database contains the names of over 23,000 doctors who were mentioned most often. Find top-rated doctors in the fifty largest metropolitan areas, in over thirty-five specialties, and more.
National Cancer institute
Anatomy of the Lymph System
Non-Hodgkin's Lymphoma Awareness Ribbon
Consumers' Guide to Top Doctors finds the Doctors Rated Best by other Doctors in over 30 specialties.
database of 23,000 top-rated physicians by
Doctors database of 23,000 top-rated
(over 35 different fields included) Specialty
National Cancer Institute
Illustration of the lymphatic system (neck to upper thigh shown), which is part of the body's immune system.
Consumers' Guide to Hospitals
Which Hospital Should You Choose (or Avoid)?
What makes the Consumers' Guide to Hospitals so special?
We've got 30 million answers to that question. That's how many hospital records Consumers' CHECKBOOK sifted through to calculate risk-adjusted death rates and adverse-outcome rates, and that's just part of the data used to rate the hospitals. The organization also sent out more than 280,000 questionnaires to physicians in 53 major metropolitan areas in the United States, asking them to rate their local hospitals; checked ratings of the hospitals by surveyed consumers; checked which hospitals were providing recommended tests and procedures for patients with specified medical problems; and more."
AARP The Magazine